NASDAQ:MLTX
MoonLake Immunotherapeutics Stock Company Profile
$39.03
+0.370 (+0.96%)
At Close: May 21, 2024
Information
Dorfstrasse 29
Zug 6300
www.moonlaketx.com
Industry: Biotechnology
Sector: Healthcare
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
